|1.||Nicoletti, Ferdinando: 2 articles (04/2015 - 05/2014)|
|2.||Mangano, Katia: 2 articles (04/2015 - 05/2014)|
|3.||Parfenova, Helena: 2 articles (02/2015 - 10/2007)|
|4.||Leffler, Charles W: 2 articles (02/2015 - 10/2007)|
|5.||Fedinec, Alexander L: 2 articles (02/2015 - 10/2007)|
|6.||Motterlini, Roberto: 2 articles (09/2012 - 02/2005)|
|7.||Fagone, Paolo: 1 article (04/2015)|
|8.||Cavalli, Eugenio: 1 article (04/2015)|
|9.||Mammana, Santa: 1 article (04/2015)|
|10.||Barcellona, Maria Luisa: 1 article (04/2015)|
04/01/2015 - "The present study strongly supports the development of CORM-A1 as a potential new drug for treatment of patients with non-infectious posterior uveitis. "
04/01/2015 - "We show here that CORM-A1 under a late prophylactic regime is able to significantly ameliorate the natural course of experimental autoimmune uveoretinitis, a rodent model of immunoinflammatory posterior uveitis. "
03/01/2011 - "This study suggests that the use of CORM-A1 might represent a novel therapeutic strategy for the treatment of multiple sclerosis."
03/01/2011 - "We have evaluated the effects of the carbon monoxide-releasing molecule CORM-A1 [Na(2) (BH(3) CO(2) ); ALF421] on the development of relapsing-remitting experimental allergic encephalomyelitis (EAE) in SJL mice, an established model of multiple sclerosis (MS). "
09/01/2012 - "Although both CORM-A1 and CORM-3 (30 µmol/kg) decreased platelets accumulation in thrombus, only CORM-A1 (3-30 µmol/kg) inhibited platelet activation to phosphatidylserine on their surface. "
09/01/2012 - "The antiaggregatory effect of CORM-A1, but not CORM-3, correlated positively with weight of the thrombus. "
09/01/2012 - "CORM-A1 (10-30 µmol/kg, i.v.), in a dose-dependent fashion, significantly decreased weight of electrically induced thrombus in rats, whereas CORM-3 inhibited thrombosis only at the highest dose used (30 µmol/kg). "
12/01/2014 - "CORM-2 and CORM-3 enhanced the velocity of clot formation and thrombus strength in a similar manner, whereas CORM-A1 did not affect coagulation. "
09/01/2012 - "CORM-3 and CORM-A1 inhibited thrombosis in vivo, however CORM-A1, which slowly releases carbon monoxide, and displayed a relatively weak hypotensive effect had a more pronounced antithrombotic effect associated with a stronger inhibition of platelet aggregation associated with a decrease in active plasminogen activator inhibitor-1 concentration. "
02/01/2015 - "CORM-A1 (2 mg/kg) was given to piglets via an oral gastric tube 10 minutes before or 20 minutes after seizure onset. "
02/01/2015 - "Overall, enteral supplements of CORM-A1 before or during seizures offer a novel effective therapeutic option to deliver cytoprotective mediator CO to the brain, reduce injury to endothelial and astrocyte components of cerebral blood flow regulation and to improve the cerebrovascular outcome of neonatal seizures."
02/01/2015 - "We investigated whether enteral supplements of CORM-A1 can improve cerebrovascular outcome of bicuculline-induced seizures in newborn piglets. "
02/01/2015 - "Enteral supplements of a carbon monoxide donor CORM-A1 protect against cerebrovascular dysfunction caused by neonatal seizures."
10/01/2007 - "Cerebroprotective effects of the CO-releasing molecule CORM-A1 against seizure-induced neonatal vascular injury."
|2.||Plasminogen Activators (Plasminogen Activator)
|5.||tricarbonyldichlororuthenium (II) dimer